Skip to content

5-MeO-DMT: all studies

Page 3 of 110: studies 21 to 30 of 1,096, newest first. Back to the 5-MeO-DMT overview

Research

A Critical Evaluation of the Hypothesis that N,N-Dimethyltryptamine Maintains Neuroplasticity

Zenodo (CERN European Organization for Nuclear Research) June 24, 2026 Ramiro Solis preprint

The brain’s ability to rewire itself, neuroplasticity, declines dramatically with age. Children learn faster; adults get stuck in patterns; older adults struggle to adapt. The reasons for this decline remain unclear. In a companion paper (Solis, 2026a), I critically evaluated the broad hypothesis that N,N-dimethyltryptamine (DMT) has endogenous physiological functions. The evidence was found to...

Impact of CYP2D6 Polymorphisms on the Pharmacokinetics of N,N-Dimethyltryptamine and Harmine via PBPK Modeling and Simulation

Future Pharmacology June 23, 2026 Gabriella de Souza Gomes Ribeiro, Pieter Annaert, Frederico Severino Martins et al.

Background/Objectives: In this study, we present an analysis of ayahuasca, a psychedelic preparation containing N,N-dimethyltryptamine (DMT) and β-carbolines, such as harmine (HRM), a reversible monoamine oxidase A (MAO-A) inhibitor that enables the oral bioavailability of DMT. CYP2D6 is a highly polymorphic enzyme associated with interindividual variability in drug exposure, but its influence...

DOI: 10.3390/futurepharmacol6030034 (opens in new tab) Harmine Pharmacokinetics Cmax Cyp2d6 +5

Synthesis and BiologicalEvaluation of 4‑Bromo-N,N-dimethyltryptamine(4-Br-DMT): A Synthetic BuildingBlock for Future Analog Development

Figshare June 23, 2026 Elena Bray, Grant C. Glatfelter, Alexander D. Maitland et al.

The ongoing psychedelic renaissance has prompted a renewed search for novel drugs based on modifying existing psychedelic motifs. In this study, a synthesis of 4-bromo-N,N-dimethyltryptamine (4-Br-DMT) was achieved and used as a late-stage intermediate for analog development. Specifically, we were able to synthesize and access novel molecules by forming carbon–carbon bonds at the C4 position...

DOI: 10.1021/acsomega.6c02996.s001 (opens in new tab) Serotonergic Tryptamines The renaissance Safety profile +5

A Critical Evaluation of the Hypothesis that N,N-Dimethyltryptamine has Endogenous Functions

Zenodo (CERN European Organization for Nuclear Research) June 22, 2026 Ramiro Solis preprint

The human body possesses enzymatic machinery to both synthesize and rapidly degrade N,N-dimethyltryptamine (DMT). This coexistence raises a question: does DMT serve an endogenous function, or is it a metabolic byproduct with no physiological role? DMT is structurally almost identical to serotonin and binds to the same serotonin receptors. Serotonin is universally accepted as a neurotransmitter...

DOI: 10.5281/zenodo.20823985 (opens in new tab) Serotonin Endogeny Endogenous agonist 5-HT Receptor +5

Genome-based optimization of psilocybin and N,N-dimethyltryptamine biosynthetic pathways in E. coli using CRISPR-associated transposases

Metabolic Engineering June 14, 2026 Zachary N. Abrahms, Mohammad Majdi, Siena M. Madsen et al.

Stable, high-level biosynthesis of complex natural products requires precise control of heterologous pathway expression, yet transcriptional architectures optimized on plasmids often fail when transferred to the chromosome. Here, we present ePathIntegrate, a genome-centric pathway engineering strategy that leverages CRISPR-associated transposases (CASTs) to integrate and rebalance multigene...

DOI: 10.1016/j.ymben.2026.102490 (opens in new tab) Psilocybin Transposase Escherichia coli Biosynthesis +4

Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: A randomised [ 18 F]FDG-PET study

Universität Zürich, ZORA June 1, 2026 Klemens Egger, Robert Bozsak, Helena Aicher et al.

Classical psychedelics such as N,N -dimethyltryptamine (DMT) modulate consciousness via serotonergic receptor agonism, and are increasingly investigated for their psychotherapeutic potential. When combined with the monoamine oxidase A (MAO-A) inhibitor harmine—mimicking the pharmacological profile of ayahuasca—oral DMT induces a psychedelic experience lasting 4–5 h. While some neuroimaging...

DOI: 10.5167/uzh-434709 (opens in new tab) Harmine Placebo Neuroimaging Metabolite +9

Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: A randomised [18F]FDG-PET study.

Journal of Cerebral Blood Flow & Metabolism June 1, 2026 Klemens Egger, Robert Bozsak, Helena Aicher et al.

Classical psychedelics such as N,N-dimethyltryptamine (DMT) modulate consciousness via serotonergic receptor agonism, and are increasingly investigated for their psychotherapeutic potential. When combined with the monoamine oxidase A (MAO-A) inhibitor harmine-mimicking the pharmacological profile of ayahuasca-oral DMT induces a psychedelic experience lasting 4-5 h. While some neuroimaging...

Speech markers of psychological change following a psychedelic 5-MeO-DMT retreat.

Journal of Psychopharmacology May 23, 2026 Joanna Kuć, Rosalind McAlpine, Amelia Sellers et al.

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), a potent, short-acting psychedelic, induces profound shifts in cognition, affect, and self-awareness. Because language explicitly expresses these domains and voice implicitly conveys them, both may serve as potential 'biomarkers' of behavioural change. This study introduces a novel framework for analysing baseline language and vocal features, pre-...

Therapeutic properties of ayahuasca component N,N-Dimethyltryptamine in a pre-clinical model of Parkinson's disease

DIGITAL.CSIC (Spanish National Research Council (CSIC)) May 12, 2026 Javier Calleja‐conde, Víctor Echeverry‐alzate, Marina Sanz-Sancristóbal et al.

Parkinson's disease is a progressive neurodegenerative disorder with increasing global prevalence, primarily driven by population ageing. A hallmark of the disease is the degeneration of nigrostriatal dopaminergic neurons, accompanied by marked activation of glial cells and a sustained neuroinflammatory response. Current pharmacological treatments are limited to symptomatic relief and do not...

DOI: 10.1016/j.expneurol.2026.11582 (opens in new tab) Ayahuasca Neuroprotection Hallucinogen Dopaminergic +10

Therapeutic properties of ayahuasca component N,N-Dimethyltryptamine in a pre-clinical model of Parkinson's disease.

Experimental Neurology May 12, 2026 Javier Calleja‐conde, Víctor Echeverry‐alzate, Marina Sanz-Sancristóbal et al.

Parkinson's disease is a progressive neurodegenerative disorder with increasing global prevalence, primarily driven by population ageing. A hallmark of the disease is the degeneration of nigrostriatal dopaminergic neurons, accompanied by marked activation of glial cells and a sustained neuroinflammatory response. Current pharmacological treatments are limited to symptomatic relief and do not...